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Abstract
Background: Despite advances in our understanding of basic mechanisms driving post-surgical pain, treating
incision-induced pain remains a major clinical challenge. Moreover, surgery has been implicated as a major cause
of chronic pain conditions. Hence, more efficacious treatments are needed to inhibit incision-induced pain and
prevent the transition to chronic pain following surgery. We reasoned that activators of AMP-activated protein
kinase (AMPK) may represent a novel treatment avenue for the local treatment of incision-induced pain because
AMPK activators inhibit ERK and mTOR signaling, two important pathways involved in the sensitization of
peripheral nociceptors.
Results: To test this hypothesis we used a potent and efficacious activator of AMPK, resveratrol. Our results
demonstrate that resveratrol profoundly inhibits ERK and mTOR signaling in sensory neurons in a time- and
concentration-dependent fashion and that these effects are mediated by AMPK activation and independent of
sirtuin activity. Interleukin-6 (IL-6) is thought to play an important role in incision-induced pain and resveratrol
potently inhibited IL-6-mediated signaling to ERK in sensory neurons and blocked IL-6-mediated allodynia in vivo
through a local mechanism of action. Using a model of incision-induced allodynia in mice, we further demonstrate
that local injection of resveratrol around the surgical wound strongly attenuates incision-induced allodynia.
Intraplantar IL-6 injection and plantar incision induces persistent nociceptive sensitization to PGE2 injection into the
affected paw after the resolution of allodynia to the initial stimulus. We further show that resveratrol treatment at
the time of IL-6 injection or plantar incision completely blocks the development of persistent nociceptive
sensitization consistent with the blockade of a transition to a chronic pain state by resveratrol treatment.
Conclusions: These results highlight the importance of signaling to translation control in peripheral sensitization of
nociceptors and provide further evidence for activation of AMPK as a novel treatment avenue for acute and
chronic pain states.
Background
Incision associated with surgery causes acute pain and
surgery has been identified as a potential major cause of
chronic pain conditions [1-3]. Between 10 and 50% of
patients develop chronic pain following surgical proce-
dures such as groin hernia repair, breast and thoracic
surgery, leg amputation, or coronary artery bypass
surgery [2]. Despite improvements in post-surgical pain
treatment strategies, the incidence of moderate to severe
pain after surgery is still high in several patient popula-
tions [4,5]. Moreover, the exact mechanisms involved in
the development of persistent pain following surgery
have not been elucidated. Interleukin 6 (IL-6), a pro-
inflammatory cytokine, is a significant mediator of noci-
ceptive plasticity in pre-clinical pain models and is
implicated in several human pain conditions. Serum IL-
6 levels increase significantly in patients immediately
after surgery [6-8] and circulating IL-6 levels are pro-
portional to the extent of tissue injury during an
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operation, rather than being proportional to the dura-
tion of the surgical procedure itself [9]. Furthermore,
IL-6 levels have been shown to be elevated in skin
around incision sites [10,11] and it has been implicated
in preclinical incision-induced pain models [12-14].
Although these reports are suggestive of involvement of
IL-6 in post-surgical pain, the precise mechanisms by
which IL-6 drives post-surgical pain are poorly under-
stood. However, IL-6 has been implicated as an impor-
tant player in many preclinical pain models and elegant
genetic studies have demonstrated that IL-6’s pain pro-
moting qualities are mediated by IL-6 receptors
expressed by nociceptors [15,16].
Recently we demonstrated that IL-6 causes induction
of nascent protein synthesis in primary afferent neurons
and their axons which can contribute to increased noci-
ceptive sensitivity [17]. We have also shown that AMP-
activated protein kinase (AMPK) activators reverse
mechanical allodynia in neuropathic pain models and
that these compounds negatively regulate protein synth-
esis in sensory afferents [18]. AMPK, the energy sensor
of the cell, is a heterotrimeric Ser/Thr protein kinase
activated by alterations in cellular AMP: ATP ratio.
Once activated, AMPK inhibits ATP consuming ana-
bolic processes such as protein translation [19]. AMPK
activation achieves these effects largely through inhibi-
tion of mammalian target of rapamycin (mTOR) signal-
ing [19] but AMPK activation has also been linked to
inhibition of mitogen activated protein kinase (MAPK)
signaling [18,20]. We hypothesized that activation of
AMPK signaling pathway may represent a novel phar-
macological mechanism for the treatment of post-surgi-
cal pain.
To test this hypothesis, we have utilized resveratrol, a
natural polyphenol found in red grapes and wine, which
has previously been shown to increase AMPK activity in
neurons [21]. Although several studies originally
described resveratrol as an activator of sirtuin enzymes,
which are NAD-dependent deacetylases [22-25] these
results have been challenged based on lack of specificity
in screening assays [26,27]. Moreover, several recent in
vivo studies strongly suggest that resveratrol effects are
independent of sirtuins. On the other hand, resveratrol
is a highly potent and efficacious activator of AMPK
[28-30] and its metabolic effects are dependent on a
subunit AMPK expression suggesting that AMPK is the
major target for resveratrol in vivo [31]
Herein, we demonstrate that resveratrol activates
AMPK and suppresses translation regulation pathways
in sensory neurons in a dose-dependent, time-dependent
and reversible manner. We also show that resveratrol
inhibits both acute and persistent sensitization in an IL-
6-induced hyperalgesic priming model as well as in a
model of postsurgical pain. These findings suggest that
resveratrol may have utility in the treatment of post-sur-
gical pain and further implicate AMPK as a novel target
for the development of analgesics.
Results
Resveratrol suppresses signaling to translation machinery
in sensory neurons
While resveratrol has been shown to stimulate AMPK
and inhibit mTOR signaling in cell-lines and some
neural tissues, its effect on sensory neurons is unknown.
Hence, we first asked whether resveratrol treatment
influenced AMPK activity or signaling pathways
involved in regulating cap-dependent protein translation
in cultured trigeminal ganglion (TG) neurons from mice
grown in the presence of NGF (50 ng/ml) for 5 days.
TG cultures were treated with vehicle or increasing con-
centrations (10, 30 or 100 μM) of resveratrol (Figure 1)
for 1 h. Resveratrol activated AMPK in a dose depen-
dent manner (Figure 1A) and suppressed activity in sig-
naling pathways that promote cap-dependent
translation. Specifically, these changes included signifi-
cantly decreased phosphorylation of extracellular signal
regulated kinase (ERK, Figure 1B) and its downstream
target involved in translation control eukaryotic initia-
tion factor (eIF) 4E (Figure 1C). Resveratrol also
decreased AKT (Figure 1D), mTOR (Figure 1E) and
tuberin sclerosis protein 2 (TSC2, Figure 1F) phosphory-
lation indicating negative regulation of the mTOR path-
way in TG neurons. Consistent with this notion, eIF4E
binding protein (4EBP, Figure 1G) and ribosomal S6
protein (rS6p, Figure 1I), which are downstream mTOR
targets, demonstrated decreased phosphorylation upon
resveratrol treatment. Finally, resveratrol increased
eIF4G phosphorylation(Figure 1H), an effect that can
occur independently of mTOR signaling [32] and that is
uncoupled from eIF4G-mediated eIF3 recruitment
[33,34]. We have observed similar effects with other
AMPK activators (e.g. A769662) [18]. Thus, in cultured
TG neurons, resveratrol activates AMPK and suppresses
signaling via the ERK and mTOR pathways to transla-
tion machinery suggesting a concentration-dependent
inhibition of cap-dependent translation by resveratrol in
sensory neurons.
Having established a concentration-dependent effect
of resveratrol on TG neurons in culture, we next asked
whether these effects were time dependent. Resveratrol,
at a maximally effective dose (100 μM), was applied to
TG neurons for 10, 30 or 100 min and activity in signal-
ing pathways was assessed by Western blot (Figure 2).
Resveratrol activated AMPK maximally at 10 and 30
min treatment (Figure 1A). Similarly, resveratrol sup-
pressed activity in the ERK (Figure 2B and 2C) and
mTOR pathways (Figure 2D-I) over the time course of
resveratrol exposure.
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Because resveratrol led to a profound inhibition of
ERK and mTOR signaling pathways, we next asked
whether this effect is reversible. TG cultures were trea-
ted with resveratrol for 1 h followed by 1 or 2 h wash-
out periods. Resveratrol led to a reversible activation of
AMPK (Figure 3A) and a reversible inhibition of both
ERK (Figure 3B and 3C) and mTOR signaling (Figure
3D-H). Hence, resveratrol dose- and time-dependently
activates AMPK and inhibits ERK and mTOR signaling
in a reversible fashion in sensory neurons.
Finally, we asked whether resveratrol treatment leads
to an inhibition of cap-dependent translation in TG
neurons. Cap-dependent translation requires eIF4F com-
plex formation on the 5’cap structure of mRNAs [35]
and this can be assayed with a cap pull-down assay that
assesses eIF4G and 4EBP binding to eIF4E [36]. The
eIF4F complex is composed of eIF4E bound to eIF4A
and eIF4G whereas 4EBP binding to eIF4E is indicative
of inhibition of cap-dependent translation because 4EBP
represses eIF4A and 4 G binding to eIF4E [35]. Resvera-
trol treatment for 1 h led to a profound increase in
4EBP binding to eIF4E and a parallel decrease in
eIF4G binding (Figure 4A-C). Hence, resveratrol
concentration-dependently inhibits eIF4F complex for-
mation in sensory neurons consistent with inhibition of
cap-dependent translation.
Resveratrol-mediated inhibition of ERK and mTOR does
not require Sirt1
While the above results strongly suggest that resveratrol
acts via activation of AMPK, there have been conflicting
reports suggesting that resveratrol produces its effect by
activation of Sirt1, a NAD-dependent deacetylase
[22-25]. To assess whether Sirt1 may play a role in this
process we utilized a Sirt1 inhibitor to ask whether it
would block the effects of resveratrol on ERK and
mTOR signaling. Trigeminal primary neuronal cultures
were pre-treated for 1 h and then co-treated with nicoti-
namide (10 mM), which inhibits Sirt1, in the presence
of resveratrol (100 μM) for 1 h (Table 1). Nicotinamide
co-incubation had no effect on resveratrol-mediated
activation of AMPK or inhibition of ERK or mTOR sig-
naling. Likewise, if resveratrol activates Sirt1, Sirt1 acti-
vators should be able to recapitulate effects produced by
resveratrol. Hence, to further rule out a role for Sirt1,
TG cultures were treated with vehicle or a Sirt1
Figure 1 Resveratrol suppresses ERK and mTOR signaling in sensory neurons in a concentration-dependent manner. Treatment of TG
neurons with resveratrol (10, 30, and 100 μM) for 1 h induces a concentration-dependent increase in phosphorylation of AMPK (A). Resveratrol
treatment significantly decreases the phosphorylation of ERK (B), eIF4E (C), AKT (D), mTOR (E), TSC2 (F) 4EBP (G) and rS6p (I) but increases eIF4G
phosphorylation (H).
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activator, CAY10602 [37] (20 and 60 μM) for 1 h. Treat-
ment with CAY10602 did not change AMPK, mTOR or
ERK levels (Table 2). These results rule out a role for
Sirt1 in resveratrol mediated regulation of AMPK, ERK
and mTOR signaling and support the conclusion that
resveratrol engages AMPK signaling to inhibit ERK and
mTOR in primary sensory neurons.
Resveratrol blocks IL-6-induced signaling and IL-6-
mediated allodynia
Multiple lines of evidence indicate that IL-6 is an
important mediator of nociceptive plasticity in postsur-
gical pain. While the results above demonstrate that
resveratrol decreases ERK and mTOR signaling in TG
neurons, it is not known whether resveratrol is capable
of blocking signaling via ERK or mTOR engaged by
extracellular signals. Hence, we asked whether resvera-
trol blocks IL-6-induced changes ERK/eIF4E signaling in
primary afferent neurons [17]. Pretreatment of the TG
cultures with resveratrol (100 μM, 15 min) and
subsequent co-treatment with IL-6 (50 ng/ml, 15 min)
completely blocked IL-6 mediated phosphorylation of
ERK and eIF4E in TG cultures (Figure 5). These find-
ings indicate that resveratrol blocks IL-6-induced signal-
ing in sensory neurons.
Because resveratrol inhibits IL-6-mediated ERK/eIF4E
signaling in sensory neurons we hypothesized that
resveratrol would inhibit IL-6-mediated allodynia in
vivo. Intraplantar injection of IL-6 (0.1 ng) produces
acute mechanical allodynia that lasts for ~ 3 d, with
complete resolution by day 4 (Figure 6A). Co-injection
with resveratrol (0.1 μg or 1 μg or 10 μg) dose-relatedly
blocked IL-6-induced allodynia (Figure 6A and 6B).
There was no statistically significant difference between
resveratrol and vehicle treated groups. Hence, resvera-
trol blocks both IL-6-mediated signaling via the ERK/
eIF4E pathway and IL-6-induced allodynia. These find-
ings suggest that resveratrol may be an efficacious com-
pound for use in pain conditions linked to IL-6
signaling, such as post-incisional pain.
Figure 2 Suppression of ERK and mTOR signaling by resveratrol is time dependent. TG neurons were treated with 100 μM resveratrol for
0, 10, 30, and 100 min. Resveratrol induces an increase in phosphorylation of AMPK (A) maximally with 10 and 30 min treatment. Resveratrol
decreases the phosphorylation of ERK (B), eIF4E (C), AKT (D), mTOR (E), TSC2 (F) 4EBP (G) and rS6 (I) and this effect is time-dependent. Resveratrol
increased eIF4G phosphorylation (H).
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Resveratrol inhibits allodynia in a mouse model of post-
surgical pain
The above results predict that resveratrol should be
effective in blocking allodynia in a model of post-surgi-
cal pain. We utilized a mouse model of incisional pain
to assess if resveratrol can prevent development of allo-
dynia following the plantar incision. Animals received a
plantar incision on the left hindpaw. Resveratrol (1 μg
or 10 μg) or vehicle was injected into the paw around
the incision either immediately following incision and
24 hrs post surgery or 1 and 3 days following incision.
Mice with plantar incision that received vehicle dis-
played mechanical allodynia lasting for at least 9 days.
In contrast, animals that received resveratrol at the time
of incision and again 1 day later showed blunted allody-
nia and this effect was dose-related (Figure 7A and 7B).
Moreover, administering resveratrol 1 and 3 days follow-
ing incision significantly inhibited mechanical allodynia
induced by incision (Figure 7C). No changes in thresh-
old were observed in sham animals receiving resveratrol.
These results assert that resveratrol can be a potentially
efficacious treatment for post-surgical pain.
Resveratrol blocks persistent sensitization induced by IL-6
injection and plantar incision
Persistent pain is a common feature experienced by
many patients undergoing surgical procedures [2].
Figure 3 Suppression of ERK and mTOR signaling by resveratrol is reversible. TG neurons were treated with 100 μM resveratrol for 1 h
followed by 1 or 2 h washout periods. Effects of resveratrol were reversible in all cases upon 1 h washout.
Figure 4 Resveratrol suppresses eIF4F complex formation in
sensory neurons. TG neurons were treated with resveratrol (10, 30
and 100 μM) for 1 h. A) Western blot for eIF4G, 4EBP and eIF4E
from trigeminal neurons co-precipitated using 7-methyl-GTP
conjugated beads. B) Resveratrol induces a significant increase in
4EBP (negative regulator of translation) association with the cap-
binding protein eIF4E in a dose-dependent manner. C) Resveratrol
induces a significant decrease in eIF4G association with the cap-
binding protein eIF4E (a component of eIF4F complex) in a dose-
dependent manner.
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Therefore, we assessed if resveratrol is effective in block-
ing persistent sensitization induced by IL-6 injection and
plantar incision. Persistent sensitization can be revealed
by, among other stimuli, a second intraplantar injection
of inflammatory mediator, in this case PGE2 (100 ng),
after the resolution of initial allodynia [38]. For the IL-6
induced persistent sensitization, co-treatment of resvera-
trol with IL-6 on Day 1 abolished the IL-6 induced per-
sistent sensitization following PGE2 injection on day 6
(Figure 8A). Similarly, in the incision model, treatment
with resveratrol at the time of incision and 1 day later
or 1 and 3 days following incision both abolished persis-
tent sensitization precipitated by PGE2 injection 14 days
after incision. Hence, resveratrol not only inhibits allo-
dynia induced by IL-6 or plantar incision but it also
blocks the development of persistent nociceptive
sensitization.
Discussion
The present findings make a compelling case for the use
of resveratrol as a local treatment for both incision
induced pain and prevention of chronic pain induced by
incision. They show that resveratrol potently and
efficaciously inhibits ERK and mTOR signaling in sen-
sory neurons in vitro. The mTOR [39-42] and ERK
pathways [43] have been linked to pathology in multiple
preclinical pain models and our previous findings
strongly implicate these pathways in the induction of
mechanical allodynia by IL-6 and NGF [17,44] and the
development and maintenance of nerve-injury induced
allodynia [18]. The pharmacological action of resveratrol
observed in our in vitro experiments is linked to activa-
tion of AMPK and in vivo effects are consistent with
engagement of AMPK. We have previously implicated
AMPK activation in alleviation of neuropathic pain [18],
hence, the findings described herein expand the poten-
tial clinical usefulness of AMPK activators into the area
of post-surgical pain. We conclude that diverse pharma-
cological mechanisms for activation of AMPK may have
utility as novel analgesics for a variety of pain
conditions.
Anabolic processes, such as protein synthesis, are
orchestrated by upstream kinases that signal to the
translation machinery [35] such as mTOR and ERK.
These kinases can be targeted individually by selective
Table 1 Sirt1 inhibition does not reverse resveratrol-induced effects on TG neurons.
Antibody Vehicle nicotinamide 10 mM + resveratrol 100 μM resveratrol 100 μM
p-AMPK/AMPK 100 ± 7.3 199.8 ± 28.1 222.4 ± 40.0
p-ERK/ERK 100 ± 11.8 41.8 ± 8.5 ** 47.2 ± 8.8 **
p-eIF4E/eIF4E 100 ± 5.4 27.6 ± 4.7 *** 30.2 ± 6.2 ***
p-AKT/AKT 100 ± 6.2 11.6 ± 3.1 *** 12.5 ± 2.4 ***
p-mTOR/mTOR 100 ± 4.4 70.6 ± 4.4 * 62.9 ± 6.4 **
p-TSC2/TSC2 100 ± 8.3 26.6 ± 4.2 *** 36.5 ± 5.2 ***
p-4EBP/4EBP 100 ± 2.3 38.5 ± 3.0 *** 37.9 ± 7.2 ***
p-rS6p/rS6p 100 ± 7.0 33.9 ± 5.9 *** 36.5 ± 6.8 ***
TG neuronal cultures were pre-treated with nicotinamide or vehicle for 1 h and then co-treated with nicotinamide (10 mM), a sirt1 inhibitor, in the presence of
resveratrol for 1 h. The phosphorylated levels of AMPK, ERK, eIF4E, AKT, mTOR, 4EBP and rS6p were unchanged by nicotinamide
Table 2 Sirt1 activators fail to recapitulate resveratrol-
induced effects on TG neurons.
Antibody Vehicle CAY10602 20 μM CAY10602 60 μM
p-AMPK/AMPK 100 ± 13.6 95.0 ± 14.4 107.3 ± 16.6
p-ERK/ERK 100 ± 6.50 117.2 ± 5.91 126.4 ± 3.32 *
p-eIF4E/eIF4E 100 ± 13.0 105.9 ± 17.1 102.0 ± 17.0
p-AKT/AKT 100 ± 11.8 105.8 ± 5.0 107.2 ± 7.5
p-mTOR/mTOR 100 ± 8.8 103.8 ± 17.0 125.7 ± 18.5
p-TSC2/TSC2 100 ± 3.3 97.8 ± 6.8 115.1 ± 5.2
p-4EBP/4EBP 100 ± 8.3 126.2 ± 11.1 122.9 ± 8.5
p-eIF4G/eIF4G 100 ± 14.1 76.2 ± 13.8 109.0 ± 16.7
p-rS6p/rS6p 100 ± 12.5 120.3 ± 6.8 134.0 ± 10.5
TG neuronal cultures were treated with the sirt1 activator, CAY10602 (20 and
60 μM) for 1 h. The phosphorylated levels of AMPK, ERK, eIF4E, AKT, mTOR,
4EBP and rS6p were not changed by CAY10602
Figure 5 Resveratrol blocks IL-6 induced signaling in sensory
neurons. TG neuron cultures were pre-treated with resveratrol (100
μM, 15 min) followed by subsequent co-treatment with IL-6 (50 ng/
ml, 15 min). Western blot for eIF4E (A) and ERK (B) from TG neurons
treated with IL6 and/or resveratrol. Resveratrol blocked IL-6
mediated phosphorylation of eIF4E and ERK in TG cultures.
Tillu et al. Molecular Pain 2012, 8:5
http://www.molecularpain.com/content/8/1/5
Page 6 of 12
inhibitors or they can be negatively modulated by endo-
genous signaling factors that act on these pathways [45].
A crucial kinase for negative regulation of translation is
the ubiquitous, energy-sensing kinase AMPK. Activation
of AMPK by depletion of cellular nutrients or through
pharmacological intervention results in a dampening of
signaling to the translation machinery [45]. This is the
natural cellular response to energy deprivation wherein
high AMP levels signal to AMPK thereby shutting down
anabolic processes when nutrient levels are low. AMPK
is not solely regulated by cellular homeostatic mechan-
isms as it can also be targeted pharmacologically via a
number of investigational compounds (e.g. AICAR and
A769662 [46]), natural products (resveratrol [29,30])
and by the widely clinically available and safe drug met-
formin [47,48]. AMPK negatively regulates mTOR via
activation of mTOR’s negative regulator, TSC2 [49].
This results in a profound inhibition of mTOR and its
downstream targets involved in translation control (e.g.
4EBP and ribosomal S6 kinase and rS6p [49]). Activa-
tion of AMPK also negatively regulates ERK activity
induced by growth factors and cytokines [20]. This likely
occurs via phosphorylation of the insulin receptor sub-
strate 1 (IRS1) protein at Serine 789 [50]. IRS-1 is a cri-
tical component of the signaling module of all tyrosine
kinase receptors (Trks) and is linked to GP130 (the IL-6
Figure 6 Local resveratrol blocks IL-6 induced acute allodynia
in a dose-related manner. A) Intraplantar injection of IL-6 (0.1 ng)
and co-treatment with resveratrol (0.1, 1 and 10 μg) blocks IL-6
induced allodynia. B) Area under the curve (AUC) analysis shows
that resveratrol reduces IL-6 induced allodynia in a dose-related
manner.
Figure 7 Local resveratrol blocks plantar incision-induced
allodynia in a dose-related manner. Animals received a plantar
incision on the left hindpaw. Resveratrol (1 μg or 10 μg) or vehicle
was injected into the paw around the incision either immediately
following incision and 1 day post incision (A, B) or 1 and 3 days
following incision (C). A) Resveratrol injection (1 μg or 10 μg)
immediately following incision and 1 day post incision significantly
blocked plantar incision induced allodynia in a dose-dependent
manner. B) Area under the curve (AUC) analysis showing dose-
related effects in A. C) Resveratrol injection (10 μg) on day 1 and 3
following incision significantly blocks plantar incision induced
allodynia. Red arrows show times of resveratrol injection.
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signal transduction receptor) signaling [51]. This inter-
action may explain the inhibitory effect of resveratrol on
IL-6-mediated ERK/eIF4E signaling observed here.
Hence, engaging AMPK with potent activators of this
pathway (e.g. resveratrol) represents a unique opportu-
nity to achieve inhibition of pain-related signaling
because it harnesses the cell’s natural mechanism for
dampening signaling in two pathways strongly impli-
cated in pain amplification in the periphery, ERK [43]
and mTOR [18,39-42].
Accordingly, we hypothesized that AMPK activators
may represent a novel tool for the treatment of post-
surgical pain. We chose to focus on resveratrol for these
experiments because resveratrol is a potent and effica-
cious activator of AMPK [30]. Our findings clearly
demonstrate that local application of resveratrol to the
site of incision reduces mechanical allodynia, and,
importantly, prevents the transition to a chronic pain-
like state as measured by PGE2 precipitated persistent
nociceptive sensitization. These findings are consistent
with previous experiments where we have shown that
inhibition of translation regulation signaling during the
initiation of allodynia induced by IL-6 or IL-6 and NGF
prevents the development of persistent nociceptive sen-
sitization, which, importantly, can be precipitated by a
variety of stimuli, not solely PGE2 [44,52]. In fact, preci-
pitation of persistent nociceptive sensitization following
incision can be induced by administration of opioid
antagonists suggesting that precipitation does not even
require subsequent injury [53]. Moreover, we have
recently shown that AMPK activators reduce peripheral
nerve injury-induced allodynia and decrease excitability
of sensory neurons in vitro [18]. While here, and in our
previous work [18], we have largely ascribed the effects
of AMPK activators to sensory neurons, we cannot rule
out potential effects on other cell types in the behavioral
effects observed. These findings collectively create a
compelling case for the further exploration and develop-
ment of AMPK activators for the treatment of post-sur-
gical pain.
While the pharmacological action of resveratrol has
been an area of controversy, most evidence now points
to AMPK as the major target of resveratrol. As
described above, much attention was originally paid to
resveratrol as an activator of sirtuins, in particular sirt1.
However, subsequent studies have questioned these ori-
ginal results and recent studies in transgenic animals
point to AMPK as a requisite component of resveratrol
signaling [31]. Resveratrol, stimulates AMPK in a liver
kinase B1 (LKB1) -dependent fashion, similar to the
upstream activation of AMPK by metformin [30,54]. We
found that resveratrol stimulates AMPK in TG neurons
in a concentration- and time-dependent fashion and
that this AMPK activation is correlated with decreased
Figure 8 Resveratrol blocks IL-6- and plantar incision-induced
persistent sensitization. A) Intraplantar injection of IL-6 (0.1 ng)
with resveratrol (10 μg) co-treatment on Day 1 abolished the IL-6
induced persistent sensitization precipitated by PGE2 injection on
day 6. B) Intraplantar injection of resveratrol (10 μg) at the time of
incision and 1 day post incision abolished plantar incision-induced
persistent sensitization precipitated by PGE2 injection on day 14
after incision. C) Intraplantar injection of resveratrol (10 μg) on day 1
and 3 post incision abolished plantar incision induced persistent
sensitization precipitated by PGE2 injection on day 14 after incision.
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ERK and mTOR signaling, events that we have pre-
viously shown are stimulated by other AMPK activators
in TG and DRG neurons [17,18]. Inhibition or activation
of sirt1 failed to inhibit or recapitulate the effects of
resveratrol, respectively, ruling out an effect of sirtuins
in our experiments. Several other mechanisms of action
have been ascribed to resveratrol including inhibition of
inducible cyclooxygenase [55] and inhibition of cyclin-
dependent kinase 5 [56]. It is unlikely that these
mechanisms contribute to the inhibition of ERK and
mTOR signaling that we have observed in TG neurons
in vitro; however, we cannot exclude the potential con-
tribution of these effects of resveratrol to our behavioral
results. Finally, resveratrol has been shown to possess
voltage gated-sodium channel inhibition properties [57].
This effect has a slow onset (minutes of drug application
is needed), which could be a result of slowly developing
direct block of sodium channels, but is more consistent
with AMPK activation. In support of the latter conclu-
sion, we have shown that other AMPK activators induce
a profound decrease in sensory neuron excitability via a
suppression of ramp-current evoked spiking [18].
Conclusion
Several previous reports have demonstrated an anti-allo-
dynic or anti-hyperaglesic effect of resveratrol in precli-
nical pain models including the formalin model [58],
complete Freund’s adjuvant-induced inflammation [59]
and nucleus pulposus-induced allodynia [60]. While,
again, several mechanisms of action have been ascribed
to resveratrol in these assays, our in vitro findings pro-
vide novel evidence linking resveratrol’s anti-allodynic
effects in the periphery to ERK and mTOR inhibition
via activation of AMPK. Because resveratrol has poor
bioavailability that can be sensitive to physiological fac-
tors when given systemically [61], we focused on its
local effects in incision-induced pain. Resveratrol is a
natural product that can be made in different prepara-
tions for human use (it is currently sold as a dietary
supplement). Based on our present results, we propose
that preparations of resveratrol for local use in post-sur-
gical pain situations may be clinically useful in a similar
fashion (but with obviously different mechanisms of
action) to highly purified capsaicin surgical wound infu-
sions [62]. Such preparations may afford inhibition of
nociceptor sensitization and protect against a transition
to chronic pain induced by surgery.
Materials and methods
Experimental animals
Male ICR mice (Harlan, 20-25 g) were used for the
study. All animal procedures were approved by the
Institutional Animal Care and Use Committee of The
University of Arizona and were in accordance with
International Association for the Study of Pain
guidelines.
Behavior testing
For the testing, animals were placed in acrylic boxes
with wire mesh floors and allowed to habituate for
approximately 1 h on all testing days. Paw withdrawal
thresholds were measured using calibrated von Frey fila-
ments (Stoelting, Wood Dale, IL) by stimulating the
plantar aspect of left hind paw using the up-down
method [63].
IL-6 priming and behavior testing
A mouse model for ‘hyperalgesic priming’ originally
developed by Levine and colleagues [for review see [52]]
and adapted for mice [38] was used for the study. Base-
line mechanical thresholds of the left hind paw were
measured prior to IL-6 injection. For acute sensitization
experiments, IL-6 (0.1 ng) was injected into the plantar
surface of the left hind paw in a volume of 25 μl (diluted
in saline). Resveratrol (0.1, 1, or 10 μg) or vehicle was co-
injected with IL-6 and paw withdrawal thresholds were
measured at 1 h, 3 h, 24 h, 48 h and 72 h post injection.
For persistent sensitization experiments animals received
an injection of PGE2 (100 ng) in the plantar surface of
left hind paw in a volume of 25 μl 4 days following initial
intraplantar injection. Following PGE2 injection, paw
withdrawal thresholds were again measured at 1 h, 3 h
and 24 h following the PGE2 injection.
Plantar incision and behavioral testing
Prior to surgery all animals were assessed for paw with-
drawal thresholds. A mouse model of incisional pain
was used for this study [64]. A 5 mm longitudinal inci-
sion was made with a number 11 blade through skin,
fascia and muscle of the plantar aspect of the hindpaw
in isoflurane-anesthetized rats. Sham controls under-
went the same procedure but without the incision. The
skin was apposed with 2 sutures of 5 mm silk. Animals
received intraplantar injection of resveratrol or vehicle
around the incision at times indicated after incision.
Animals were allowed to recover for 24 hrs and then
paw withdrawal thresholds were measured at 24 hrs, 48
hrs, 72 hrs, 5, 7, 9, 11, and 13 days post-surgery. For
persistent sensitization experiments, the animals
received an intraplantar injection of PGE2 (100 ng/25
μl) 14 days following incision or sham procedures. The
paw withdrawal thresholds were again measured at 1 h,
3 h and 24 h following the PGE2 injection.
Primary neuronal cultures
Mouse trigeminal ganglia (TG) were excised aseptically
and placed in Hank’s Buffered Salt Solution (HBSS,
Invitrogen) on ice. The ganglia were dissociated
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enzymatically with collagenase A (1 mg/ml, 25 min,
Roche) and collagenase D (1 mg/ml, Roche) with papain
(30 U/ml, Roche) for 20 min at 37°C. To eliminate deb-
ris 70 μm (BD) cell strainers were used. The dissociated
cells were resuspended in DMEM/F12 (Invitrogen) con-
taining 1× pen-strep (Invitrogen), 1× GlutaMax, 3 μg/ml
5-FDU (Sigma), 7 μg/ml uridine (Sigma), 50 ng/ml NGF
(Millipore) and 10% fetal bovine serum (Hyclone). The
cells were plated in 6-well plates (BD Falcon) and incu-
bated at 37°C in a humidified 95% air/5% CO2 incuba-
tor. Cultures were maintained in resuspension media
until time of treatment. For experiments where resvera-
trol treatments were done alone, cultures were main-
tained in the continuous presence of nerve growth
factor (NGF) at a concentration of 50 ng/ml. NGF was
excluded for IL-6 experiments. On day 5 the cells were
washed in DMEM/F12 media for 30 mins and subse-
quently were treated as described in results.
Western blotting
Protein was extracted from cells in lysis buffer (50 mM
Tris HCl, 1% Triton X-100, 150 mM NaCl, and 1 mM
EDTA at pH 7.4) containing protease and phosphatase
inhibitor mixtures (Sigma) with an ultrasonicator on ice,
and cleared of cellular debris and nuclei by centrifuga-
tion at 14,000 RCF for 15 min at 4°C. 15 μg of protein
per well were loaded and separated by standard 7.5% or
10% SDS-PAGE. Proteins were transferred to Immobi-
lon-P membranes (Millipore) and then blocked with 5%
dry milk for 3 h at room temperature. The blots were
incubated with primary antibody overnight at 4°C and
detected the following day with donkey anti-rabbit anti-
body conjugated to horseradish peroxidase (Jackson
Immunoresearch). Signal was detected by ECL on che-
miluminescent films. Each phosphoprotein was normal-
ized to the expression of the corresponding total protein
on the same membrane. Densitometric analyses were
performed using Image J software (NIH).
5’ mRNA cap complex analysis
After the protein extraction, 50 μg protein was incu-
bated with 7- methyl GTP Sepharose 4B beads (GE
Healthcare) in the presence of 100 μM GTP for 2 h at
4°C. Unconjugated sepharose 4B beads were used for
the negative controls. The beads were then pelleted and
washed twice with lysis buffer. After a final centrifuga-
tion the pellet was suspended in 1× Laemmli Sample
Buffer containing 5% v/v b-mercaptoethanol and eIF4E,
eIF4G, eIF4A and 4EBP bound to the precipitated beads
was analyzed by western blotting.
Drugs and primary antibodies
Resveratrol was from Cayman Chemical; mouse 2.5S
NGF was from Millipore; The following rabbit
polyclonal antibodies were obtained from Cell Signaling:
p-ERK (Thr202/Tyr204, cat# 4377), total ERK, p-eIF4E
(Ser209, cat# 9741), total eIF4E, p-mTOR (Ser2448, cat#
2971), total mTOR, p-4EBP(Thr37/46, cat # 9459), total
4EBP, p-eIF4G (Ser1108, cat# 2441), total eIF4G, p-AKT
(Ser473, cat# 4058), total AKT, GAPDH and eIF4A.
Statistical Analysis and Data Presentation
Data are shown as means and the standard error of the
mean (± SEM) of eight independent cell culture wells, 6
tissue samples (for in vivo Western blotting, eIF4F com-
plex formation and nascent protein synthesis) or 6 ani-
mals (for behavioral studies). Graph plotting and
statistical analysis used Graphpad Prism Version 5.03
(Graph Pad Software, Inc. San Diego, CA, USA). Statisti-
cal evaluation was performed by one- or two-way analy-
sis of variance (ANOVA), followed by appropriate post-
hoc tests. The a priori level of significance at 95% confi-
dence level was considered at p < 0.05.
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